BGPT: Meta-analysis: anal HPV vaccine efficacy evidence map

Explore by Goal

Quick Explanation Copied

I can’t produce a “meta-analysis: anal HPV vaccine efficacy evidence map” from the provided research corpus, because none of the included sources contain analytic estimates of **vaccine efficacy/effectiveness** against **anal HPV outcomes** (e.g., incident anal HPV infection, persistent infection, or anal HSIL/AIN/cancer). The provided items are mainly **narrative reviews** on anal HPV natural history/screening and one **cross-sectional ART-era HPV prevalence/genotype** study in HIV+ MSM.

Long Explanation

Meta-analysis feasibility check: “Anal HPV vaccine efficacy evidence map”

From the provided research data, there are no analytic vaccine efficacy/effectiveness results for anal HPV outcomes. So a quantitative efficacy evidence map (effect sizes, pooled estimates, risk-of-bias meta-analytic tables) can’t be constructed without additional vaccine-efficacy papers.

1) What the provided corpus actually contains (evidence-type map)

Included items relevant to “anal HPV” here are primarily (i) narrative reviews on anal HPV natural history/screening/treatment and (ii) a cross-sectional study of anal HPV prevalence/genotypes in HIV+ MSM with ART-associated correlates—not vaccine efficacy.

Narrative reviews:
Cross-sectional analytic study:

2) Anal HPV prevalence/genotype context (what can be mapped from provided data)

The only direct numeric “endpoint-like” content here is anal HPV prevalence and genotype frequencies in HIV+ MSM (GAIA). I’m showing those as an input for designing a vaccine-efficacy evidence map later (you’d want vaccine RCTs/cohorts measuring changes in incidence/persistence or lesions).

Source: GAIA reports any-HPV prevalence 89.3% (191/214) and HPV-16 as the most common high-risk genotype (20.1%, 43/214), with HPV-18 and HPV-51 each at 14.0% (30/214).

3) Why a vaccine-efficacy evidence map is impossible from this dataset

Hard constraint: a vaccine-efficacy evidence map requires study-level analytic outputs such as effect sizes (e.g., hazard ratios, relative risks) for vaccinated vs unvaccinated, or RCT estimates, and consistent endpoints (incidence/persistence of anal HPV, or anal HSIL/AIN/cancer outcomes). None of the provided items include such estimates for anal outcomes.

The narrative reviews emphasize prevalence, diagnostics, and general prevention/need for more prospective evidence; the GAIA study measures prevalence/genotype correlates (not vaccine effect).

4) Quality/fit scoring across the provided “anal HPV” sources (evidence strength for efficacy mapping)

This is not risk-of-bias for meta-analysis (we don’t have the underlying study methods for all efficacy trials), but a pragmatic “fit-to-question” view based on the provided source metadata (narrative review vs prevalence cohort).

Fit rationale: GAIA provides genotype/prevalence endpoints (useful for context), while reviews/roadmaps generally don’t provide vaccine-specific analytic effect sizes for anal outcomes.

5) What I need from you (to actually do the requested meta-analysis map)

Provide either:

URLs/DOIs (or PDFs) for studies with anal HPV vaccine efficacy/effectiveness (RCTs or cohorts measuring anal infection persistence/incident infection, or anal HSIL/AIN/cancer).
Or confirm a scope such as: “quadrivalent vs bivalent HPV vaccines; endpoints: anal HPV persistence or HSIL/AIN; population: MSM/HIV+ or general.”

Once available, I can build an actual evidence map: endpoints → effect sizes → study quality → risk-of-bias → pooled estimates (with subgroup analyses).

Optional: run a Science AI agent anyway

If you upload/attach additional vaccine-efficacy papers, the agent can iteratively extract endpoints/effect sizes and construct the true efficacy evidence map.

Feedback:

Updated: April 20, 2026

Top Data Sources Export MCP

1. This narrative review synthesizes current knowledge on anal human papillomavirus (HPV) infection, its prevalence across populations (notably MSM and HIV-infected individuals), diagnostic approaches including anal cytology and high-resolution anoscopy (HRA), HPV genotype distribution (with HPV16 predominance), associated lesions such as HSIL/AIN 2/3, risk factors, screening considerations, and treatment options, and highlights gaps and future directions including the potential impact of vaccinati... [2016]

7QualityResults Limitations Context Blindspots Methods Sample Conflict

↗ Paper Review ↗ Full Paper

2. HPV infection underlies anal cancer and its precursor AIN; high-grade AIN is a precursor to cancer, but data from heterosexual men and non-HIV-positive women are scarce, calling for multicentre prospective studies to define progression and inform screening. [2012]

6QualityResults Limitations Context Blindspots Methods Sample

↗ Paper Review ↗ Full Paper

3. The EUROGIN 2011 roadmap provides a comprehensive review of the burden of HPV-related diseases and outlines evidence-based recommendations for the prevention and treatment of HPV-associated cancers, emphasizing the need for effective screening and vaccination strategies. [2012]

8QualityResults Limitations Methods Sample Conflict

↗ Paper Review ↗ Full Paper

4. A cross-sectional study of 214 HIV-positive men who have sex with men in Mexico City found an extremely high anal HPV prevalence and identified integrase strand transfer inhibitor (INSTI)-based ART as independently associated with reduced HPV-16 infection and with lower risk for several other high-risk genotypes, while protease inhibitors (PI) showed a mixed association; immune status and behavioral factors also influenced genotype-specific HPV risk. [2025]

7QualityResults Limitations Context Blindspots Methods Sample Conflict Data

↗ Paper Review ↗ Full Paper

5. This study uses Trio-GCTA on up to ~23,200 Norwegian parent-offspring trios to disentangle direct (offspring) and indirect (maternal and paternal) genetic effects on children's educational achievement across 8th-grade national tests and 10th-grade GPA, revealing substantial direct effects, additional indirect parental effects, and positive gene-environment correlations within families. [2025]

9QualityResults Limitations Context Blindspots Methods Sample Conflict Data

↗ Paper Review ↗ Full Paper

Key Insight

Even before meta-analysis, the limiting step can be endpoint specificity: “anal HPV vaccine efficacy” requires studies that measure anal infection/persistence or anal HSIL/AIN outcomes—reviews and prevalence studies cannot substitute for that analytic evidence.

Keep Exploring

Which specific anal HPV vaccine efficacy endpoints (incidence vs persistence vs HSIL/AIN vs cancer) are most consistently reported across studies, and how do endpoint definitions vary?

How do ART regimen, immune status, and baseline genotype multiplicity modify vaccine-efficacy estimates in stratified meta-analysis?

Analysis Wizard

Not applicable: the requested meta-analysis requires additional vaccine-efficacy study effect sizes not present in the provided dataset, so no extraction/plotting code can produce valid efficacy pooling yet.

Hypothesis Graveyard

Cross-sectional prevalence reduction alone will reliably estimate vaccine efficacy against anal cancer risk; rejected because vaccine impact can act through persistence/lesion progression dynamics, not necessarily one-time prevalence measurements.

Narrative reviews can provide enough quantitative inputs for meta-analysis; rejected because they lack extractable study-level effect sizes and consistent endpoint definitions.

Potential Experiments

Design a longitudinal observational cohort stratified by vaccination status and baseline anal HPV genotype set; primary endpoint is incident persistence (clearance vs persistence over predefined intervals) rather than prevalence at one timepoint; analyze with hazard models adjusting for ART/immune status.

Collect anal cytology/HRA outcomes plus genotype data at multiple timepoints; compare vaccinated vs unvaccinated trajectories of HSIL/AIN emergence and genotype persistence; pre-register endpoint definitions and use standardized assay panels to reduce measurement bias.

Science Art

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

I may be overly strict about requiring analytic vaccine efficacy endpoints because that’s necessary for valid meta-analysis; this reduces output when the evidence is incomplete.

Stay current without chasing every paper.

Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.

The Evidence Layer for Scientific AI

Ask questions across claims linked to experiments, exact results, limitations, and sources.Know what the science actually supports before you trust the answer.

Explore by Goal

Quick Explanation Copied

Long Explanation

Meta-analysis feasibility check: “Anal HPV vaccine efficacy evidence map”

1) What the provided corpus actually contains (evidence-type map)

2) Anal HPV prevalence/genotype context (what can be mapped from provided data)

3) Why a vaccine-efficacy evidence map is impossible from this dataset

4) Quality/fit scoring across the provided “anal HPV” sources (evidence strength for efficacy mapping)

5) What I need from you (to actually do the requested meta-analysis map)

Optional: run a Science AI agent anyway

Top Data Sources ExportMCP

2. HPV infection underlies anal cancer and its precursor AIN; high-grade AIN is a precursor to cancer, but data from heterosexual men and non-HIV-positive women are scarce, calling for multicentre prospective studies to define progression and inform screening. [2012]

3. The EUROGIN 2011 roadmap provides a comprehensive review of the burden of HPV-related diseases and outlines evidence-based recommendations for the prevention and treatment of HPV-associated cancers, emphasizing the need for effective screening and vaccination strategies. [2012]

6. Depleting the essential Vibrio cholerae GTPase CgtA under nutrient stress triggers broad transcriptional and proteomic stress responses that drastically reduce growth and viability while inducing persistence, with the C-terminal domain modulating chemotaxis and motility. [2023]

7. The study presents 'tacg', a command-line tool designed for efficient pattern matching in DNA sequences, enabling sophisticated searches for various motifs and patterns while being faster and more portable than existing alternatives. [2002]

8. This study investigates the influence of polymorphisms in the PAG gene on liver function, ammonia production, and the risk of overt hepatic encephalopathy in cirrhotic patients. [2007]

9. Domain dependent orchestrated regulation of bacterial growth, persistence and chemotaxis by an essential GTPase, CgtA, in Vibrio cholerae [2021]

Ask a Follow-Up

Key Insight

Even before meta-analysis, the limiting step can be endpoint specificity: “anal HPV vaccine efficacy” requires studies that measure anal infection/persistence or anal HSIL/AIN outcomes—reviews and prevalence studies cannot substitute for that analytic evidence.

Keep Exploring

Which specific anal HPV vaccine efficacy endpoints (incidence vs persistence vs HSIL/AIN vs cancer) are most consistently reported across studies, and how do endpoint definitions vary?

How do ART regimen, immune status, and baseline genotype multiplicity modify vaccine-efficacy estimates in stratified meta-analysis?

Analysis Wizard

Not applicable: the requested meta-analysis requires additional vaccine-efficacy study effect sizes not present in the provided dataset, so no extraction/plotting code can produce valid efficacy pooling yet.

Hypothesis Graveyard

Cross-sectional prevalence reduction alone will reliably estimate vaccine efficacy against anal cancer risk; rejected because vaccine impact can act through persistence/lesion progression dynamics, not necessarily one-time prevalence measurements.

Narrative reviews can provide enough quantitative inputs for meta-analysis; rejected because they lack extractable study-level effect sizes and consistent endpoint definitions.

Potential Experiments

Collect anal cytology/HRA outcomes plus genotype data at multiple timepoints; compare vaccinated vs unvaccinated trajectories of HSIL/AIN emergence and genotype persistence; pre-register endpoint definitions and use standardized assay panels to reduce measurement bias.

Science Art

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

I may be overly strict about requiring analytic vaccine efficacy endpoints because that’s necessary for valid meta-analysis; this reduces output when the evidence is incomplete.

Stay current without chasing every paper.

My BGPT

Trending

Top Data Sources Export MCP